✦ LIBER ✦

Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial

✍ Scribed by Benhamou, Y.; Moussalli, J.; Ratziu, V.; Lebray, P.; De Backer, K.; De Meyer, S.; Ghys, A.; Luo, D.; Picchio, G. R.; Beumont, M.

Book ID: 121669782
Publisher: University of Chicago Press
Year: 2013
Tongue: English
Weight: 346 KB
Volume: 208
Category: Article
ISSN: 0022-1899
DOI: 10.1093/infdis/jit274

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Telaprevir Activity in Treatment-Naive P

Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4

✍ Sefcik, R. K.; Bichoupan, K.; Martel-Laferriere, V.; Odin, J. A.; Liu, L. U.; Pe 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 60 KB

Antiviral activity of telaprevir and boc

Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients

✍ Hélène Fontaine; Stanislas Pol 📂 Article 📅 2011 🏛 Elsevier 🌐 French ⚖ 154 KB

P.268 Treatment of patients infected wit

P.268 Treatment of patients infected with hepatitis C virus genotype 4 in Portugal — retrospective study

✍ H. Gloria; J. Areias; F. Augusto; A. Carvalho; M.C. Moura; H. Guerreiro; L. Lebr 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Randomized Controlled Trial of Danoprevi

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

✍ Marcellin, Patrick; Cooper, Curtis; Balart, Luis; Larrey, Dominique; Box, Terry; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 517 KB

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu

A simple rule to personalize standard du

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial

✍ Francioso, Simona; Almerighi, Cristiana; Forte, Paolo; Bandiera, Franco; Nosotti 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 738 KB